OREANDA-NEWS. By operation of Nasdaq Listing Rule 5815(a)(1)(B), the shares of KaloBios Pharmaceuticals, Inc., (KBIO) will be suspended from The Nasdaq Stock Market effective at the open of business on January 13, 2016. Any open GTC orders will be cancelled.

Trading in the company’s securities has been halted since December 17, 2015. The trading halt will no longer be in effect upon the suspension, which would allow the company’s securities to be eligible for trading in the over-the-counter markets under the symbol KBIOQ.